Market Place
Sourcing Support
Pfizer`s BRAFTOVI + MEKTOVI Shows Long-Term Response In NSCLC
14 Sep 2024 //
BUSINESSWIRE
Erasca Announces Three Presentations at the 2024 ASCO Annual Meeting
24 Apr 2024 //
GLOBENEWSWIRE
EMA validates Pierre Fabre`s MAA for BRAFTOVI
02 Nov 2023 //
PR NEWSWIRE
US clears Pfizer`s Braftovi, Mektovi combo for use in lung cancer
13 Oct 2023 //
BUSINESSWIRE
Encorafenib/Binimetinib Combo Highlights Novel Therapies for BRAF V600+ NSCLC
31 Aug 2023 //
ONCLIVE
Sandoz`s Generic Encorafenib Receives Approval in the U.S.
17 Jul 2023 //
FDA
FDA Approves FoundationOne Liquid CDx as a Companion Diagnostic for BRAFTOVI
09 Jun 2023 //
BUSINESSWIRE
Erasca Announces Trial Collabo & Supply Agreement Pierre Fabre ERAS-007
30 Nov 2022 //
GLOBENEWSWIRE
Pfizer and Strata expand clinical partnership for cancer trial
14 Sep 2022 //
CLINICALTRIALSARENA
Amber Specialty Added to Pfizer’s Limited Distribution Network
03 Aug 2022 //
BUSINESSWIRE
FDA Confirms Para IV Patent Litigation for Encorafenib capsules.
26 Jul 2022 //
FDA
EORTC and Pierre Fabre launch phase 3 trial for melanoma
27 May 2022 //
PMLIVE
Pierre Fabre & EORTC open a large Phase III clinical study the adjuvant setting
24 May 2022 //
PRESS RELEASE
FDA expands Lilly`s Erbitux label with Braftovi to treat metastatic CRC
30 Sep 2021 //
PHARMABIZ
Erasca Announces Clinical Trial Collaboration and Supply Agreement with Pfizer
08 Sep 2021 //
GLOBENEWSWIRE
BRAFTOVI Approved in South Korea for Treatment of Colorectal Cancer
20 Aug 2021 //
PRESS RELEASE
NICE backs Braftovi for BRAF-positive colorectal cancer
23 Nov 2020 //
ENDPTS
NICE says yes to Braftovi combination for colorectal cancer
20 Nov 2020 //
PHARMAPHORUM
Pfizer to present clinical trials of 18 approved & investigational medicines
13 May 2020 //
PHARMABIZ
New Data from 18 Approved and Invg Pfizer Medicines to be Showcased at ASCO20
12 May 2020 //
PRESS RELEASE
U.S. FDA Approves BRAFTOVI® (Encorafenib) in Combination with Cetuximab
09 Apr 2020 //
BUSIBNESSWIRE
U.S. FDA APPROVES BRAFTOVI® (ENCORAFENIB) IN COMBINATION WITH CETUXIMAB
08 Apr 2020 //
PFIZER
US FDA grants priority review status to Pfizer`s sNDA for Braftov
19 Dec 2019 //
PHARMABIZ
U.S. FDA Accepts and Grants Priority Review to sNDA for BRAFTOVI
18 Dec 2019 //
BUSINESS WIRE
EMA validated Pierre Fabre’s application for a Braftov and Mektovi combination
08 Nov 2019 //
PHARMATIMES
Pierre Fabre to Present New Data at the ESMO Annual Congress
25 Sep 2019 //
BUSINESSWIRE
HSE reimburses Braftovi combo
23 Aug 2019 //
PHARMA TIMES
Darzalex, Ibrance among latest SMC decisions
09 Jul 2019 //
PHARMATIMES
Pierre Fabre`s triplet therapy makes strong showing in colorectal cancer
09 Jul 2019 //
PHARMAFILE
Array BioPharma’s Triple-Drug Combo Could be Gamechanger for Colorectal Cancer
08 Jul 2019 //
BIOSPACE
Pierre Fabre and its partner Array BioPharma announce interim analysis results
06 Jul 2019 //
BUSINESSWIRE
Array played with Pfizer’s eagerness to land a deal on time
01 Jul 2019 //
FIERCE PHARMA
BeiGene and a Pfizer spinout launch a newco to develop a MEK/BRAF inhibitor
18 Jun 2019 //
ENDPTS
Pfizer, ‘never say never’ with big M&A, inks $11.4B Array cancer deal
18 Jun 2019 //
FIERCE PHARMA
Array BioPharma Announces Presentation of Updated from the Ph3 COLUMBUS
29 May 2019 //
PR NEWSWIRE
Array Biopharma`s Braftovi triple therapy meets both endpoints
22 May 2019 //
PHARMAFILE
Array BioPharma`s colorectal cancer combo treatment meets main goals
22 May 2019 //
REUTERS
BRAFTOVI+MEKTOVI Recommended by NCCN Guidelines for Colorectal Cancer
18 Mar 2019 //
PR NEWSWIRE
NICE recommends Pierre Fabre`s Braftovi in BRAF V600-mutated advanced melanoma
22 Jan 2019 //
PHARMA FILE
NICE OK for Bravtovi skin cancer drug
18 Jan 2019 //
PHARMA TIMES
Pierre Fabre`s Braftovi (Encorafenib) receives approval in Europe
12 Oct 2018 //
EMA
EU approves new option for metastatic melanoma
24 Sep 2018 //
PHARMA TIMES
Pierre Fabre Receives EU Approval for BRAFTOVI® + MEKTOVI®
22 Sep 2018 //
BUSINESSWIRE
Meeting highlights from the CHMP 23-26 July 2018
31 Jul 2018 //
EMA
Onco360 Selected for Encorafenib & Binimetinib Limited Distrbn Pharmacy Network
02 Jul 2018 //
BUSINESSWIRE
Pierre Fabre-Array BioPharma Announce Addl Results of Encorafenib & Binimetinib
04 Jun 2018 //
BUSINESSWIRE
Pierre Fabre and Array BioPharma Announce COLUMBUS Phase 3 Study Results
17 May 2018 //
BUSINESSWIRE
